The Technical Sales Specialist (Gene Therapy) is responsible for driving early-stage adoption and market penetration of Sartorius’ Advanced Therapy Solutions portfolio across Japan. This role acts as a technical-commercial enabler, positioning Sartorius as a partner of choice for biopharma, biotech, CDMO, academic, and hospital stakeholders developing gene and nucleic acid-based therapies.
This is a strategic, customer-facing role focused on identifying new opportunities, engaging early-stage customers, and supporting the commercial organization in converting technical engagement into sustainable business growth.

The Technical Sales Specialist is a field-based role who pursues and converts new business through hands‑on technical selling, running demos and trials that directly drive revenue and product adoption within a defined portfolio, as well as handing over newly won accounts for long‑term development in collaboration with Central Sales.

Grow with us – Your Responsibilities:

Identify, reach, and engage prospective customers, including new‑logo and whitespace opportunity generation in collaboration with Central Sales, to generate and qualify new business opportunities through proactive technical hunting, ensuring structured communication with Central Sales for subsequent account management where applicable
Plan, execute, and manage technical demos and trials to validate customer fit and accelerate adoption
Drive deal progression by framing solution fit, quantifying customer impact, and addressing technical objections to increase win rate through technical selling and value positioning
Drive deal progression by framing solution fit, quantifying customer impact, and addressing technical objections to increase win rate through technical selling and value positioning, promoting the defined product and service portfolio to demonstrate technical fit with customer requirements
Shape customer proposals and commercial offers in collaboration with Central Sales by providing critical technical inputs that impact deal closure
Deliver pre‑ and post‑sales technical support to secure adoption and generate repeat revenue, ensuring a smooth transition to Central Sales once adoption is secured, working in coordination with established technical support functions
Capture and share actionable Voice-of-Customer insights (user needs, feedback, competitive signals) to influence assigned product portfolio and enhance sales enablement approaches, sharing insights systematically with Central Sales for integration into account plans

What will convince us:

Master’s degree in Life Sciences, Biotechnology, Engineering or related field, or equivalent demonstrated professional experience
Strong familiarity with Gene Therapy processes and the development of gene and nucleic acid-based therapies
3+ years of technical sales, applications support, or pre‑sales experience in a scientific or technical environment
Demonstrated hunter mindset with proven ability to identify, advance, and win new opportunities
Strong hands‑on technical capability, including demos, trials, and customer evaluations
Excellent consultative communication skills, able to articulate technical and commercial value to diverse stakeholders
Proficiency in CRM systems and structured sales processes, with strong documentation discipline
Willingness to travel >50% as this role is heavily focused on external customers

About Sartorius

Sartorius is part of the solution in the fight against cancer, dementia, and many other diseases. Our technologies help translate scientific discoveries into real-world medicine faster, so that new therapeutics can reach patients worldwide.

We look for ambitious team players and creative minds, who want to contribute to this goal and advance their careers in a dynamic global environment.

Join our global team and become part of the solution. We are looking forward to receiving your application.
www.sartorius.com/careers

About the company

Sartorius provides laboratory and bioprocessing equipment and services for the biopharmaceutical industry. Its two divisions, Bioprocess Solutions and Lab Products & Services, supply systems, consumables, and analytics used in biotech drug and vaccine development and production. It differentiates itself with a long history, an integrated portfolio, global support, and acquisitions like BioOutsource to offer end-to-end solutions. Its goal is to help biopharmaceutical companies develop and manufacture biotech products more reliably and at scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Göttingen, Germany

Founded

1870

Get referred to Sartorius

See people who can refer or advise you

Simplify's Take

What believers are saying

H1 2026 operational sales rose 7.7%, and management reaffirmed full-year guidance.
May 2026 bond refinancing lowered funding pressure before the €650 million maturity.
ElevateBio pilot validation and September 2026 ordering support Eveo sales conversion in 2027.

What critics are saying

Tariff refunds and customer compensation cut 2026 revenue by up to €35 million.
Lab Products grew only 5.3% operationally in H1 2026, lagging Bioprocess Solutions.
Delayed advanced-therapy orders from two customers shift revenue into 2027, hurting execution confidence.

What makes Sartorius unique

Eveo launches March 16, 2026, integrating cell therapy manufacturing and QC in one system.
Bioprocess Solutions dominates with high-recurring consumables and switching costs across biologics manufacturing.
Stedim Biotech integration gives Sartorius tighter control over single-use bioprocessing and global customer relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Flexible Work Hours
Wellness Program
Professional Development Budget

Company News

Yahoo Finance

Jul 23rd, 2026

Sartorius reports 7.7% sales growth as bioprocess equipment stabilises

Sartorius reported solid first-half results, with constant-currency sales up 7.7% and underlying EBITDA rising 3.9% as margins improved to 30.3%. Management confirmed full-year guidance. Bioprocess Solutions led performance, growing 8.3% in constant currencies. Consumables drove growth, whilst equipment stabilised slightly. Chief executive Michael Grosse said demand for biologics remains robust, particularly in monoclonal antibody manufacturing. However, advanced-therapy orders from two customers were delayed and could shift revenue into 2027. Tariff refunds and accounting effects distorted reported results but did not change underlying business trends. The company booked €26 million in customer compensation related to tariffs. Operating cash flow and free cash flow both improved sharply in the first half.

AD HOC NEWS

May 15th, 2026

Sartorius completes full takeover of Stedim Biotech, delisting bioprocessing unit from Euronext Paris

Sartorius Stedim Biotech is set to be delisted from Euronext Paris following a squeeze-out by majority shareholder Sartorius Group. The voluntary tender offer and subsequent acquisition process, which began in early 2024, will transition the company from a separately traded stock into a fully integrated part of Sartorius Group. Headquartered in Aubagne, France, Sartorius Stedim Biotech develops bioprocessing equipment and single-use technologies for biopharmaceutical manufacturing. Its products include bioreactors, filtration systems and process automation tools used by pharmaceutical and biotech companies globally. North America represents a key market, with many US-based biopharma firms using its technologies. The company experienced normalised growth following pandemic-era demand surges, with customers working through elevated inventories accumulated during vaccine production. Despite short-term headwinds, long-term demand drivers remain supported by expanding biologics and advanced therapy pipelines.

wallstreet:online AG

May 6th, 2026

Sartorius completes $560M bond placement with 3.75% coupon to refinance existing debt

Sartorius has completed a €500 million bond placement via its Dutch subsidiary Sartorius Finance B.V. The five-year bond, targeted at institutional investors, was more than four times oversubscribed and carries a 3.75% annual coupon. The life science group will use the proceeds for general corporate purposes, including refinancing existing debt. This includes the redemption of a €650 million bond with a 4.25% interest rate due in autumn 2026. Sartorius has applied for admission to trading on the Euro MTF market of the Luxembourg Stock Exchange. Chief financial officer Florian Funck said the successful issuance strengthens the company's balanced debt maturity profile and long-term financing position, whilst demonstrating investor confidence in Sartorius' strategic direction.

Sartorius

May 6th, 2026

Sartorius completes placement of bond with a volume of 500 million euros

May 6, 2026 – Sartorius has successfully issued a bond with a volume of 500 million euros via its Dutch subsidiary Sartorius Finance B.V.. The issue was targeted at institutional investors and met with strong demand, being more than 4 times oversubscribed.

Associated Press

Mar 16th, 2026

Sartorius launches platform to cut CAR-T manufacturing costs by 90% and quadruple output

Sartorius has launched the Eveo Cell Therapy Platform, an integrated system for producing autologous cell therapies including CAR-T treatments. The modular platform can increase output up to fourfold in existing cleanroom space whilst reducing manufacturing costs by approximately 90 percent. The system integrates cell selection, activation, gene modification, expansion and final formulation into a closed system. Its compact design allows a single operator to process eight patient batches simultaneously in the space traditionally needed for two, potentially producing over 350 doses annually compared to today's 100 doses in the same footprint. A successful pilot with CDMO ElevateBio validated the platform's real-world applicability. Sartorius will begin taking orders in September 2026, with first deliveries expected in 2027.